Aevum Zenth Health Sciences Division

Investor Relations

Transparent reporting, disciplined capital allocation, and a pipeline engineered for sustainable value creation across biopharma and medtech.

AZPH (NYSE)
$142.85
+2.4% ▲
After Hours

FY 2024 Performance

Key metrics reflecting Zenth Pharma's operational scale and growth trajectory.

Total Revenue
$18.4B
+12.3% YoY
Adjusted EPS
$4.82
+18.7% YoY
R&D Investment
$3.1B
16.8% of Revenue
Clinical Pipeline
42 Programs
14 Phase III, 8 NDA/BLA
Free Cash Flow
$6.7B
+9.4% YoY
Dividend Yield
1.84%
Quarterly Payout

Regulatory Documents

Access quarterly reports, annual filings, proxy statements, and regulatory submissions.

PDF
2024 Annual Report (10-K)
Filed: Feb 28, 2025 · 42 MB
PDF
Q3 2025 Earnings Release
Filed: Oct 15, 2025 · 1.2 MB
PDF
Definitive Proxy Statement
Filed: Apr 10, 2025 · 8.5 MB
PDF
SEC 8-K Filings Archive
Current Quarter · Multiple Files
PDF
Sustainability & ESG Report
Published: Jan 20, 2025 · 6.1 MB
PDF
Investor Presentation Deck
Q3 2025 Conference · 14 MB

Upcoming Investor Events

Webcasts, earnings calls, and industry conferences featuring Zenth Pharma leadership.

Dec 04, 2025
Q3 2025 Earnings Call & Webcast
Live discussion of financial results, pipeline updates, and 2026 guidance. Replays available 24h post-event.
Jan 14, 2026
J.P. Morgan Healthcare Conference
Chief Medical Officer and CFO presenting at Booth 412. Pre-registered analyst meetings available.
Mar 18, 2026
Annual Shareholder Meeting
Virtual and in-person attendance options. Agenda includes executive compensation ratification and board elections.

Leadership & Governance

Experienced oversight across biopharma, finance, regulatory affairs, and strategic growth.

EC
Dr. Elena Vance
\n
Chairperson & Independent Director
AuditGovernance
MR
Marcus Rhee, PhD
CEO & Executive Director
ExecutiveStrategy
SL
Sarah Lin
CFO & Investor Relations Lead
FinanceCompensation
JK
Dr. James Kofi
Independent Director
ScientificESG
AT
Aisha Tanaka
Independent Director
RegulatoryAudit
DP
David Petrov
Independent Director
CompensationGovernance

Investor Relations Contact

For media inquiries, investor questions, or dividend reinvestment program details, please reach out to our dedicated IR team.

📧 investors@zenthpharma.com
📞 +1 (212) 555-0187
📍 Zenth Pharma Tower, 450 Park Ave, NY, NY 10022
Mon-Fri, 8:00 AM - 6:00 PM EST